Table 1.
Phase III trials of azacitidine as a single agent
Study | CALGB 9221 No. (%) | Updated CALGB No. (%) | AZA-001 No. (%) |
---|---|---|---|
No. patients | 99 | 99 | 179 |
CR | 7 (7) | 10 (10) | 30 (17) |
PR | 16 (16) | 1 (1) | 21 (12) |
HI | 37 (37) | 36 (36) | 87 (49) |
OR | 60 (60) | 47 (47) | 138 (78) |
Abbreviations: CR, complete remission; PR, partial remission; HI, hematological improvement; OR, overall response.